Skip to content

Author

Stuart J. Conway

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Discovery of a phenazine–thiol conjugase from sparse data using genome-informed machine learning

Machine learning has enabled powerful biological discoveries using models trained on large datasets. However, for many important biological questions, such as identifying enzymes that transform understudied substrates, sparsity of training data is often a major bottleneck. Here, using phenazine natural products as a case study, we show that integrating genome-informed data augmentation with contrastive learning in protein language space enables identification of phenazine-interacting proteins starting from only 14 known phenazine modifying sequences. We name this approach ML-CITO (Machine Learning for genomic Context-Informed Transferable discOvery). Applying this framework led to the discovery of PTC (Phenazine-Thiol Conjugase), the first enzyme known to catalyze phenazine thioconjugation, a phenazine modification reaction long observed but previously presumed to occur only through non-enzymatic chemistry. In silico simulation and experimental measurements demonstrate that PTC binds to both phenazine and glutathione as substrates. Recombinant expression and biochemical characterization reveal that PTC promotes glutathione-dependent modification of phenazines, yielding distinct reaction outcomes that depend on substrate identity. Although thiol-conjugated phenazine products exhibit reduced toxicity to bacterial cells, deletion of the gene encoding PTC does not confer a strong fitness disadvantage, illustrating how direct learning of sequences can uncover relevant enzymes that might evade phenotype-based genetic screens. Together, these results demonstrate that coupling comparative genomics with protein machine learning can convert “small data” typically outside the scope of machine learning into actionable predictive power, thereby facilitating enzyme discovery.

Xiaoyu Shan, I. Trindade, N. Glasser et al. · 0 citations
Open access Jul 2026

Targeting RNA-Binding Oncofetal Protein IGF2BP3: Discovery of Potent and Selective Inhibitors

Cancer remains a major global health burden and a leading cause of death worldwide, despite remarkable advances in cancer biology and therapeutics. RNA-binding proteins (RBPs) are an ideal target for cancer therapies due to their pivotal role in regulating gene expression. However, these proteins are notoriously difficult to target with small molecules, often being considered “undruggable”. IGF2BP3 is one such protein, with a well-established oncogenic role across cancer types and cancer-specific expression patterns. Despite extensive biological evaluation of this protein over the last 30 years, efforts to develop a small-molecule inhibitor for this challenging, yet critical, target have only been rarely reported. We report a structure-activity relationship (SAR) campaign that allowed us to evaluate 37 analogs of I3IN-002, a compound previously shown to bind IGF2BP3. I3IN-002 and three of the most promising compounds identified were evaluated by a cellular thermal shift assay (CETSA) with results consistent with in-cell target engagement. Pharmacokinetic properties for these four compounds were also evaluated. Beyond enabling the discovery of several new potent and selective small molecules, these studies have allowed us to elucidate key parameters for potency, selectivity, and metabolic stability that should aid future efforts in RBP drug discovery.

G. M. Scherer, Jacob P. Sorrentino, A. K. Jaiswal et al. · 0 citations